Posted by Michael Wonder on 28 Apr 2021
FDA grants priority review for Nefecon for patients with IgA nephropathy
28 April 2021 - Calliditas Therapeutics today announced that the U.S. FDA has accepted the submission and granted priority review for the new drug application for Nefecon, a down regulator of IgA1 for the treatment of IgA nephropathy.
The FDA has set a Prescription Drug User Fee Act goal date of 15 September 2021.
